Citadel's Ken Griffin Massively Boosts Eli Lilly (LLY) Position as Weight-Loss Pill Expands to UK

Key Highlights

Table of Contents

Citadel, managed by Ken Griffin, expanded its Eli Lilly holdings by acquiring an additional 704,000 shares during Q2
The hedge fund now owns 945,000 shares valued at approximately $1.18 billion, ranking LLY as its sixth-largest equity holding
Shares have surged 17% year-to-date, recently reaching record territory
The pharmaceutical company introduced Foundayo, its oral weight-management medication, to the United Kingdom—the first European market to receive it
Analyst consensus stands at Strong Buy with a mean price target of $1,375.78

Shares of Eli Lilly are currently changing hands near $1,228, representing a 17% gain for the year, following revelations that Ken Griffin’s Citadel substantially increased its holdings in the drugmaker throughout the second quarter of 2026.

Eli Lilly and Company, LLY

The investment firm acquired 704,000 additional shares during the three-month period, elevating its total ownership to 945,000 shares with a market value of $1.18 billion. This position now represents the sixth-largest holding in Citadel’s diverse portfolio of nearly 7,500 equity positions.

The strategic timing suggests Citadel capitalized on weakness in the stock. Through April’s conclusion, LLY had declined 21% year-to-date before staging a reversal. Griffin’s organization accumulated shares throughout the second quarter, with the stock subsequently experiencing substantial appreciation.

The temporary decline aligned with U.S. regulatory clearance of Foundayo, the company’s oral obesity medication. Since then, the shares have rebounded powerfully, establishing fresh all-time peaks in recent trading sessions.

The company’s portfolio of metabolic and diabetes therapeutics continues delivering exceptional performance. Revenue from these products is projected to surpass $55 billion for the current fiscal year.

UK Market Receives Foundayo

This week, Eli Lilly introduced Foundayo to the United Kingdom market, establishing the nation as Europe’s inaugural destination for the oral GLP-1 therapy. The medication, scientifically identified as orforglipron, is presently accessible through private healthcare channels.

UK regulatory authorities granted authorization for Foundayo on August 10. The approval makes it the second GLP-1 tablet option for British patients, joining Novo Nordisk’s Wegovy pill.

Monthly pricing in the UK market ranges between £100 and £120 for Foundayo. This represents a significant discount compared to Lilly’s injectable Mounjaro, which commands £330 monthly.

By comparison, private market pricing for the Wegovy tablet spans £74 to £129 monthly throughout the UK, varying by dosage strength and subscription arrangement.

Public health system availability through the NHS awaits assessment from NICE, England’s health economics evaluation body. Following its initial committee session, NICE has requested supplementary data, with no timeline established for subsequent review proceedings.

Analyst Sentiment on LLY

Current coverage from twenty Wall Street research firms yields a Strong Buy consensus rating for LLY. The rating comprises 18 Buy recommendations alongside two Hold ratings published within the most recent three-month window.

The mean analyst price target stands at $1,375.78, suggesting approximately 12% appreciation potential from present trading levels.

European Union regulatory processes for Foundayo remain ongoing. Novo Nordisk’s Wegovy tablet has secured a favorable assessment from the European Medicines Agency, though final approval from the European Commission is still forthcoming.

Across the Atlantic, U.S. cash-pay pricing for Foundayo begins at $149 monthly and scales to $349 for maximum strength formulations. A recently introduced Medicare demonstration program provides limited coverage at $50 monthly for eligible participants.

✨ Limited Time Offer